Drug Type Small molecule drug |
Synonyms ASTX 029, ASTX029 |
Target |
Mechanism ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H31ClFN5O5 |
InChIKeyBVRGQPJKSKKGIH-PUAOIOHZSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 2 | US | 31 Jul 2024 | |
Myelodysplastic-Myeloproliferative Diseases | Phase 2 | US | 31 Jul 2024 | |
Myeloproliferative Disorders | Phase 2 | US | 31 Jul 2024 | |
Acute Myeloid Leukemia | Phase 2 | US | 08 Feb 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 10 May 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | FR | 10 May 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | ES | 10 May 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | GB | 10 May 2018 | |
Solid tumor | Phase 2 | US | 10 May 2018 |
NCT03520075 (ASCO2022) Manual | Phase 1 | Solid tumor KRAS Mutation | 76 | (Phase 1A) | zurbgmenoz(apblbjmydu) = vfspdonbfc xotoqowbfv (vovwtvindf ) View more | Positive | 02 Jun 2022 |
(Phase 1B) | bwblocubar(unbdevtmqr) = nnejcisgsd idmwlzzcbn (cobapsnajy ) | ||||||
NCT03520075 (AACR2021) Manual | Phase 1 | 56 | ASTX029 | xomyysqqea(dcqodqxpud) = 1/6 at the 200 mg dose level(Cohort 5, PiB/fed)(grade 3 maculopapular rash);1 pt at the 280 mg dose level(Cohort 12, tablet/fasting)(grade 2 central serous retinopathy) yybezkwycd (ugvflkhqbu ) View more | Positive | 01 Jul 2021 |